Mystic Pharmaceuticals, Inc.
HCID Member | Medical Devices & Tech
2006 Windy Terrace
Cedar Park, TX 78613 USA
phone: 512-918-2900
fax: 512-918-2910
Symbol Private
Founded 2003
Employees 14
www.mysticpharmaceuticals.com
Research Sector Medical Devices & Tech
Summary Description
Precision unit dose drug delivery solutions for ophthalmic, intranasal and lyophilized applications
Management
Timothy Sullivan, President & Chief Executive Officer; Jeffrey Nelson, VP of Engineering; Michael Shaw, VP Manufacturing Operations
Keywords
drug delivery, injection, ophthalmology, eye, vision, intranasal applications, vaccine delivery, lyophilized delivery, drugdelivery

Comment | Printable Version | Aug. 29, 2008
If you work for Mystic Pharmaceuticals, Inc. and want to update this profile, click here

Description
Mystic is an integrated specialty pharmaceutical company specializing in novel unit dose packaging of drugs, in combination with their precision delivery systems, to provide significantly improved dose drug delivery of pharmaceuticals, biologicals, and vaccines for ophthalmic and intranasal applications. Mystic's Drug Delivery platform establishes new, advanced standards for precision dosing, ease of delivery and enhanced patient compliance
Products / Services
Mystic provides two unit dose packaging systems, the Veridoser Platform and UniDoser Platform, that can accommodate a variety of drug compounds and biological agents. These dose drug packaging units are used in combination with Mystic's precision ophthalmic and intranasal delivery systems to produce a simplified unit dose administration of drugs, which imparts enhanced user compliance. The company is also developing an intranasal vaccine delivery system for pandemic and bioterror applications for civilian and military force protection.
Technology / Differentiation
Mystic's VersiDoser Drug Delivery platform utilizes proprietary form fill manufacturing to produce sterile, preservative free, liquid filled blisters for unit dose packaging of the drug or biological agent of interest. The UniDoser Platform utilizes an aseptic blow fill seal manufacturing process to produce unit dose ampoules of drugs and biological agents. These dose packaging units are used in combination with Mystic's proprietary ophthalmic, intranasal, and lyophilized drug delivery devices for a combinatorial delivery system that provides a more precise, safer, convenient and cost effective solution for front-of-the-eye and intranasal drug delivery of pharmaceuticals, biologics and vaccines.
Market / Customers
Mystic Pharmaceuticals addresses the expanding global market demand for pharmaceutical products that are of lower cost, simplified unit dose administration and enhanced user compliance
Status
The company began unveiling in December 2006, its technologies which have been in development since 2003, and is currently in discussions with financial and strategic partners to fund commercialization of these product. To date the company has completed two primary funding rounds totaling $10M. The company expects to enter Phase III clincal trials in 2008 with first products reaching the market starting in 2010. Furthermore, Mystic is producing a pipeline of generic pharmaceuticals to be utilized with their specialized delivery system.


2008-11-23-3400